-
Posted by
Two Blokes May 4 -
Filed in
Stock
-
3 views
AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, with a probable need to raise $100M-$150M in the next 2-3 years. My base-case DCF model estimates a fair value of $8.11, offering a 179% upside, with an optimistic scenario reaching $15.38.
